<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; TBI</title>
	<atom:link href="http://www.stockbloghub.com/tag/tbi/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ACOR) Acorda Therapeutics Inks Deal with Medtronic</title>
		<link>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511</link>
		<comments>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:18:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SCI]]></category>
		<category><![CDATA[Service Corporation International]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[TrueBlue Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78511</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired worldwide development and commercialization rights to AC105. The Candidate – AC105 Acorda intends to study AC105 as an acute treatment for patients who have suffered neurological trauma, such as spinal cord injury (SCI) and traumatic brain injury (TBI). The candidate has demonstrated neuroprotective properties and improvement of locomotor function in SCI and cognitive function in TBI when therapy was initiated within four hours of injury in preclinical studies. Medtronic has evaluated the candidate in phase I studies conducted with healthy volunteers. Acorda intends to initially conduct phase II studies with the candidate for SCI. Other studies may subsequently be conducted for central nervous system indications like TBI and stroke. AC105 enjoys ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TBI) Initiating Oxygen Biotherapeutics at Outperform Rating</title>
		<link>http://www.stockbloghub.com/2009/10/26/tbi-initiating-oxygen-biotherapeutics-at-outperform-rating/18730</link>
		<comments>http://www.stockbloghub.com/2009/10/26/tbi-initiating-oxygen-biotherapeutics-at-outperform-rating/18730#comments</comments>
		<pubDate>Mon, 26 Oct 2009 22:45:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Services]]></category>
		<category><![CDATA[Staffing & Outsourcing Services]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[TrueBlue]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18730</guid>
		<description><![CDATA[We are initiating coverage of Oxygen Biotherapeutics, Inc. (OXBO) with an ‘Outperform’ rating. Despite what has been a tumultuous past for the company and a abysmal fate for competitors attempting to develop similar products, the potential upside that Oxycyte offers is too significant to ignore. Does Oxycyte do what management says it does? (Key Efficacy Question) In theory, Oxycyte has the potential to be a wonder drug &#8212; a sort of WD-40 of medicine. Preclinical data suggests that Oxycyte has astounding potential for the treatment of traumatic brain injury (TBI), decompression sickness, carbon monoxide poisoning, sickle cell crisis, organ preservation and as a neuroprotectant in patients with myocardial infarction or stroke. The effects in TBI were clearly evident in the phase I program conducted by Oxygen Bio in 2006. Initial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/tbi-initiating-oxygen-biotherapeutics-at-outperform-rating/18730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

